1. Chemotherapy-free treatments: are we ready for prime time?. (5th March 2019) Authors: Lorusso, D; Pignata, S; Gonzalez-Martin, A Journal: Annals of oncology Issue: Volume 30:Number 4(2019) Page Start: 497 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. (2nd May 2019) Authors: Colombo, N; Sessa, C; du Bois, A; Ledermann, J; McCluggage, W G; McNeish, I; Morice, P; Pignata, S; Ray-Coquard, I; Vergote, I; Baert, T; Belaroussi, I; Dashora, A; Olbrecht, S; Planchamp, F; Querleu, D Journal: Annals of oncology Issue: Volume 30:Number 5(2019) Page Start: 672 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. (2nd May 2019) Authors: Colombo, N; Sessa, C; du Bois, A; Ledermann, J; McCluggage, W G; McNeish, I; Morice, P; Pignata, S; Ray-Coquard, I; Vergote, I; Baert, T; Belaroussi, I; Dashora, A; Olbrecht, S; Planchamp, F; Querleu, D Journal: Annals of oncology Issue: Volume 30:Number 5(2019) Page Start: 672 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Adjuvant treatment of high-risk renal cell carcinoma: the jury is still out. (1st September 2018) Authors: Procopio, G; Sepe, P; Verzoni, E; Pignata, S; Bamias, A Journal: Annals of oncology Issue: Volume 29:Number 10(2018) Page Start: 2030 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PARPi related toxicities: do we need more appropriate instruments to evaluate it?. (22nd May 2018) Authors: Lorusso, D; Pignata, S Journal: Annals of oncology Issue: Volume 29:Number 8(2018) Page Start: 1613 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. (16th February 2018) Authors: Piccirillo, M C; Scambia, G; Bologna, A; Signoriello, S; Vergote, I; Baumann, K; Lorusso, D; Murgia, V; Sorio, R; Ferrandina, G; Sacco, C; Cormio, G; Breda, E; Cinieri, S; Natale, D; Mangili, G; Pisano, C; Cecere, S C; Di Napoli, M; Salutari, V Journal: Annals of oncology Issue: Volume 29:Number 5(2018) Page Start: 1189 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. (10th May 2018) Authors: Mirza, M R; Pignata, S; Ledermann, J A Journal: Annals of oncology Issue: Volume 29:Number 6(2018) Page Start: 1366 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 934OAlienor/ENGOT-ov7 randomized trial exploring weekly paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian sex cord tumors (SCT) in relapse. (23rd October 2018) Authors: Ray-Coquard, I L; Harter, P; Lorusso, D; Dalban, C; Vergote, I B; Fujiwara, K; Gladieff, L; Lueck, H-J; Floquet, A; Lesoin, A F; Schnelzer, A; Pignata, S; Selle, F; Sehouli, J; Brocard, F; Mangili, G; Pautier, P; De Giorgi, U; Provansal, M; Heudel, P-E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. LBA36Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study. (23rd October 2018) Authors: Ledermann, J A; Shapira-Frommer, R; Santin, A; Lisyanskaya, A S; Pignata, S; Vergote, I; Raspagliesi, F; Sonke, G S; Birrer, M J; Provencher, D M; Sehouli, J; Colombo, N; González-Martín, A; Oaknin, A; Ottevanger, P B; Rudaitis, V; Cristescu, R; Kobie, J; Ruman, J; Matulonis, U A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 987PTrabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of prior use of antiangiogenics: First results of an observational, prospective study. (23rd October 2018) Authors: Pignata, S; Scambia, G; Mazzei, T; Arruti Barbia, M; Naglieri, E; de Sande, L M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗